Sittingbourne, Kent, UK, 6 April 2011 - Vivacta Limited, the medical diagnostics company with a revolutionary system for point-of-care testing, announced today that it will be presenting three posters at the Oak Ridge Conference: Emerging Technologies for 21st Century Clinical Diagnostics, taking place in Baltimore, US on 14th April 2011.
The Oak Ridge Conference is the American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies, and brings together thought leaders from industry, academia, and clinical laboratories. The conference focuses exclusively on pre-commercial technologies.
The posters will be on Vivacta’s piezofilm technology platform. The innovative technology platform enables the development of next generation near-patient diagnostic and monitoring products using a novel immunoassay system for the measurement of analytes in whole-blood. Each test requires only a finger prick sample, providing actionable results within 10 minutes.
The three posters demonstrate Vivacta’s developments in the following:
- Full evaluation study of a quantitative, whole-blood POC method for Thyroid Stimulating Hormone (TSH) analysis - Small molecule detection using a pyro-optical immunoassay system with internal controls
- Second generation pyro-optical immunoassay system: improved signal-to-noise in a multiplexed cartridge
Dr Steve Ross, R&D Director at Vivacta presenting at the conference said:
“The Oak Ridge conference is renowned for attracting leading scientists and technologists to present their latest successes across a range of cutting-edge disciplines including diagnostics. We are delighted that the organisers have accepted 3 of our posters for presentation at the meeting”
About Vivacta
Vivacta Limited is applying its expertise in piezofilm technology to develop a range of new generation high performance PoC diagnostics able to deliver quantitative readings within 10 minutes from a single pin prick of blood.
The Company’s platform technology exploits the piezoelectric effect by which thermal perturbations on a piezofilm surface cause an electric charge to be produced. The measurement of this electric charge enables monitoring of chemical activity – or rate of binding between antibody and analyte – in an assay. In harnessing this piezofilm platform technology, Vivacta has developed PoC diagnostic products able to produce and present sensitive, precise and fully quantitative results, equivalent to those produced in laboratories.
Vivacta has generated an independent intellectual property position of over 10 patent families protecting the use of piezofilms in diagnostic assays. Vivacta’s investors include HBM BioVentures, IDInvest (formerly AGF), Spark Ventures and Viking.
For more information please visit www.vivacta.com
Contacts:
Vivacta
Oliver Boucher
Tel: +44 1795 419400
ob@vivacta.com
Capital MSL
Mary Clark, Justine Lamond & Hollie Vile
Tel: +44 (0)20 7307 5337
vivacta@capitalmsl.com
